Frequency Therapeutics, Inc (FREQ)

Etorro trading 970x250

About Frequency Therapeutics, Inc

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company’s lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. Address: 19 Presidential Way, Woburn, MA, United States, 01801

Frequency Therapeutics, Inc News and around…

Latest news about Frequency Therapeutics, Inc (FREQ) common stock and company :

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
21 Oct, 2021 FinancialContent

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that the first subject has been dosed in a new FX-322 Phase 2b study (FX-322-208) being conducted in a refined population of individuals with SNHL.

Add Up The Pieces: WDNA Could Be Worth $35
15 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $35.20 per unit.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)?
01 Oct, 2021 Yahoo! Finance

The big shareholder groups in Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) have power over the company. Insiders often...

NASDAQ:FREQ Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Frequency Therapeutics, Inc.
29 Sep, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of Frequency Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors
22 Sep, 2021 FinancialContent

Frequency Therapeutics Inc(NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its ...

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
22 Sep, 2021 FinancialContent

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:SPG) from Hold to Buy. In the ...

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
22 Sep, 2021 FinancialContent

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore human function, today announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing.

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

How The Parts Add Up: VHT Targets $287
10 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $286.99 per unit.

Frequency Therapeutics to Present at Upcoming Investor Conferences
08 Sep, 2021 FinancialContent

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at the following investor conferences:

Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)
30 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P. (NASDAQ:ACRX)Lifshitz Law Firm, P.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm
12 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:• Frequency Therapeutics Inc. (NASDAQ: FREQ)The company or its officers and directors made materially false and misle

Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates
12 Aug, 2021 Yahoo! Finance

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -1.96% and 26.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
12 Aug, 2021 FinancialContent

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2021.

How The Pieces Add Up: WDNA Headed For $35
10 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $35.15 per unit.

Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
04 Aug, 2021 Yahoo! Finance

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
02 Aug, 2021 FinancialContent
Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC
02 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ('Frequency' or 'the Company') (NASDAQ:FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the 'Class Period').

SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
02 Aug, 2021 FinancialContent
FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
02 Aug, 2021 Yahoo! Finance

LOS ANGELES, CA / ACCESSWIRE / August 2, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ('Frequency' or 'the Company') (NASDAQ:FREQ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021
02 Aug, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ('Frequency' or 'the Company') (NASDAQ:FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the 'Class Period').

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ
02 Aug, 2021 FinancialContent
FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
02 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), of the important August 2, 2021 lead plaintiff deadline.SO WHAT: If you purchased Frequency securities during the Class Period you may be entitled to compensation without payment of any out of ...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
02 Aug, 2021 Yahoo! Finance

Los Angeles, California--(Newsfile Corp. - August 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 16, 2020 and March

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI
02 Aug, 2021 FinancialContent
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
02 Aug, 2021 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discu
01 Aug, 2021 FinancialContent

Frequency Therapeutics, Inc (FREQ) is a NASDAQ Common Stock listed in , ,

970x250